"这就像穿上子一样":患者对炎症性肠道疾病的看法 药物坚持 药物坚持
Obreniokibo Ibifubara Amiesimaka1, Kristina Aluzaite1, Rhiannon Braund2
1Gastroenterology Research Unit, Department of Medicine, Dunedin School of Medicine (DSM), University of Otago, Dunedin, New Zealand.
Exploratory research in clinical and social pharmacy
|December 26, 2023
概括
对炎症性肠病 (IBD) 患者来说,药物坚持至关重要. 诸如副作用,复杂的治疗方案和医疗保健支持等因素显著影响IBD患者是否遵守他们的治疗计划.
科学领域:
- 胃肠病学 胃肠病学
- 患者坚持的研究研究.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 炎症性肠病 (IBD) 需要终身药物管理.
- 药物坚持 (MA) 对于有效的IBD治疗至关重要.
- 在新西兰南部的IBD患者中,很大一部分患者表现出不良的MA.
研究的目的:
- 探索IBD患者关于药物坚持的经验.
- 首次确定影响IBD患者药物坚持的关键因素.
主要方法:
- 在新西兰奥塔哥与IBD患者进行了两次焦点小组讨论 (FGD).
- 从直接现实主义的角度对数据进行反射性的专题分析.
主要成果:
- 患者认为MA对他们的健康至关重要,需要主动管理.
- 对MA的负面影响源于副作用,高药量负担和补充挑战.
- 医疗保健专业人员,社会支持网络和卫生系统因素 (例如补贴) 被确定为MA的关键促进因素.
结论:
- IBD患者的MA受患者,社会经济,疾病,治疗和卫生系统因素的复杂相互作用的影响.
- 需要多方面的干预措施来解决障碍,并在新西兰南部卫生系统内增强IBD患者中MA的促进者.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
128
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
128
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Irritable Bowel Syndrome III: Medical and Nursing Management
209
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
209
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Factors Influencing Drug Absorption: Disease States and Pharmacology
523
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
523
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145


